Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin Versus Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Latest Information Update: 26 Nov 2023
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary) ; Docetaxel; Fluorouracil
- Indications Mouth neoplasm; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Illuminate2
- 21 Nov 2023 Planned End Date changed from 30 Dec 2025 to 30 Dec 2026.
- 21 Nov 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 26 Nov 2021 New trial record